Revolution Medicines: FDA Approval Hopes Rekindled, But Valuation Stays Stretched

What happened

A June 2026 Motley Fool article highlights that Revolution Medicines' lead pancreatic cancer therapy, daraxonrasib, could secure FDA approval later this year, bolstered by over $4 billion in cash. The company's pivotal Phase 3 RASolute 302 trial is fully enrolled and on track for a 2026 readout, with Breakthrough Therapy Designation enabling a potential accelerated review. However, the latest DeepValue report assigns a 'Potential Sell' rating, citing a ~$19B market cap with no approved products, annual cash burn of ~$1.0-1.1B, and a crowded KRAS competitive landscape. The stock has already surged 122% year-to-date and trades at $98, well above the analyst consensus average target of ~$78, implying that much of the approval optimism is priced in. While near-term FDA news could provide a powerful catalyst, the risk/reward skew is unfavorable given the binary nature of pivotal data and the structural encumbrances of royalty financing.

Implication

Investors should treat any approval-related run-up as an opportunity to de-risk. The underlying thesis hinges on pivotal PDAC data later this year, and the current valuation leaves little room for error. The $4B cash cushion provides runway but does not compensate for the adverse risk/reward. A disciplined approach would be to wait for a pullback or clear data before committing new capital.

Thesis delta

The new article strengthens the near-term catalyst narrative, but our core thesis remains that the stock is overvalued relative to the probability of a successful Phase 3 outcome. The approval timeline may be accelerating, but we do not see a fundamental shift in the risk/reward: the stock still embeds high expectations and faces binary risk. We maintain our cautious stance, with a trim above $115 and attractive entry below $75.